The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

About CAPVAXIVE CAPVAXIVE is Merck’s FDA-approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of invasive disease and pneumonia in adults 18 ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or Pneumococcal 21-valent Conjugate Vaccine, for active ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for ...

Merck's Capvaxive gears up to challenge ... Elizabeth Banks stars in Pfizer's new pneumococcal vaccine awareness push. (Pfizer) “It’s up to us to lead the charge,” she says in a video ...

for its pneumococcal 21-valent conjugate vaccine, CAPVAXIVE, for use in individuals aged 18 and older. According to InvestingPro analysis, Merck maintains excellent financial health with strong cash ...